Literature DB >> 15278764

Identification of variants in cyclin D1 ( CCND1) and B-Cell CLL/lymphoma 2 ( BCL2).

Byung Lae Park1, Lyoung Hyo Kim1, Hyun Sub Cheong1, Hye Young Cho1, Eun Mi Kim1, Hyoung Doo Shin1, Yong-Sun Kim2, Chaeyoung Lee3.   

Abstract

CCND1 is an important cell-cycle regulatory protein associated with cell proliferation, poor prognosis and recurrence in cancer, while BCL2 is an important anti-apoptotic protein that plays a vital role in the regulation of the life span by controlling the rate of apoptosis. Recent studies have shown that CCND1 and BCL2 may be responsible for the body mass and the regulation of various metabolic processes. In an effort to discover additional polymorphism(s), we scrutinized the genetic polymorphisms in the CCND1 and BCL2. By direct DNA sequencing in 24 individuals, we identified 22 sequence variants within the 16 kb of whole CCND1 gene: one in exon 4, 17 in introns and four in the 3' UTR region. We also found eight sequence variants within 7.5 kb exon-intron boundaries of BCL2 gene: one in promoter, three in exon 1, and four in the 3' UTR region. Haplotypes, their frequencies and linkage disequilibrium coefficients (| D'| and r(2)), among polymorphisms were estimated. Among identified variants, seven and six variants of CCND1 and BCL2 were genotyped in a larger series of subjects ( n=320). Statistical analyses of CCND1 and BCL2 polymorphisms with two metabolic phenotypes revealed no significant association. The information concerning genetic polymorphisms of CCND1 and BCL2 might provide valuable information for future genetic studies of diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278764     DOI: 10.1007/s10038-004-0173-0

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  29 in total

1.  Mutation and linkage disequilibrium in human mtDNA.

Authors:  P Hedrick; S Kumar
Journal:  Eur J Hum Genet       Date:  2001-12       Impact factor: 4.246

2.  Expression of Bcl-2 and Bax in the human corpus luteum during the menstrual cycle and in early pregnancy: regulation by human chorionic gonadotropin.

Authors:  N Sugino; T Suzuki; S Kashida; A Karube; S Takiguchi; H Kato
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

3.  Multiplexed, high-throughput genotyping by single-base extension and end-labeled free-solution electrophoresis.

Authors:  Wyatt N Vreeland; Robert J Meagher; Annelise E Barron
Journal:  Anal Chem       Date:  2002-09-01       Impact factor: 6.986

4.  The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241.

Authors:  D Howe; C Lynas
Journal:  Haematologica       Date:  2001-06       Impact factor: 9.941

5.  Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study.

Authors:  Y Zheng; H Shen; E M Sturgis; L E Wang; S A Eicher; S S Strom; M L Frazier; M R Spitz; Q Wei
Journal:  Carcinogenesis       Date:  2001-08       Impact factor: 4.944

6.  Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism.

Authors:  Lizhong Wang; Tomonori Habuchi; Kenji Mitsumori; Zhenhua Li; Toshiyuki Kamoto; Hidefumi Kinoshita; Norihiko Tsuchiya; Kazunari Sato; Chikara Ohyama; Akira Nakamura; Osamu Ogawa; Tetsuro Kato
Journal:  Int J Cancer       Date:  2003-01-01       Impact factor: 7.396

7.  Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma.

Authors:  U Leiter; R M Schmid; P Kaskel; R U Peter; G Krähn
Journal:  Arch Dermatol Res       Date:  2000-05       Impact factor: 3.017

8.  No evidence of a functionally significant polymorphism of the BCL2 gene in Danish, Finnish and Basque type 1 diabetes families.

Authors:  P E Heding; A E Karlsen; R Veijola; J Nerup; F Pociot
Journal:  Genes Immun       Date:  2001-11       Impact factor: 2.676

9.  Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit.

Authors:  R M Zwijsen; R Klompmaker; E B Wientjens; P M Kristel; B van der Burg; R J Michalides
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

Review 10.  Bcl-2 and the regulation of programmed cell death.

Authors:  J C Reed
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

View more
  15 in total

1.  Role of Caspase 8, Caspase 9 and Bcl-2 polymorphisms in papillary thyroid carcinoma risk in Han Chinese population.

Authors:  Ying-Xue Wang; Lei Zhao; Xiu-Yun Wang; Chang-Mei Liu; Su-Guo Yu
Journal:  Med Oncol       Date:  2011-11-26       Impact factor: 3.064

2.  Association of the functional BCL-2 rs2279115 genetic variant and small cell lung cancer.

Authors:  Xinyu Yang; Feng Gao; Fei Ma; Yanli Ren; Hongwei Chen; Xue Liang; Sichong Han; Xiangyu Xiong; Wenting Pan; Changchun Zhou; Liqing Zhou; Ming Yang
Journal:  Tumour Biol       Date:  2015-08-27

3.  The -938A/A genotype of BCL2 gene is associated with esophageal cancer.

Authors:  Zhigang Liu; Ruifang Sun; Weidong Lü; Chengxue Dang; Yangrong Song; Cheng Wang; Xi Zhang; Le Han; Hao Cheng; Wei Gao; Jia Liu; Guangyan Lei
Journal:  Med Oncol       Date:  2011-12-21       Impact factor: 3.064

4.  Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity.

Authors:  Cristiane Oliveira; Gustavo Jacob Lourenço; José Augusto Rinck-Junior; Aparecida Machado de Moraes; Carmen Silvia Passos Lima
Journal:  Med Oncol       Date:  2017-01-03       Impact factor: 3.064

5.  Single Nucleotide Polymorphisms in Selected Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A Genotype-Phenotype Correlation Analysis.

Authors:  Zhibin Hu; Chunying Li; Kexin Chen; Li-E Wang; Erich M Sturgis; Margaret R Spitz; Qingyi Wei
Journal:  J Cancer Epidemiol       Date:  2008-10-29

6.  BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.

Authors:  Ning Zhang; Xiaoyan Li; Kai Tao; Liyu Jiang; Tingting Ma; Shi Yan; Cunzhong Yuan; Meena S Moran; Faming Liang; Bruce G Haffty; Qifeng Yang
Journal:  BMC Med Genet       Date:  2011-04-01       Impact factor: 2.103

7.  Functional BCL-2 regulatory genetic variants contribute to susceptibility of esophageal squamous cell carcinoma.

Authors:  Wenting Pan; Jinyun Yang; Jinyu Wei; Hongwei Chen; Yunxia Ge; Jingfeng Zhang; Zhiqiong Wang; Changchun Zhou; Qipeng Yuan; Liqing Zhou; Ming Yang
Journal:  Sci Rep       Date:  2015-07-01       Impact factor: 4.379

8.  BCL2-938C>A and CALCA-1786T>C polymorphisms in aseptic loosened total hip arthroplasty.

Authors:  Christian Wedemeyer; M D Kauther; S Hanenkamp; H Nückel; M Bau; W Siffert; H S Bachmann
Journal:  Eur J Med Res       Date:  2009-06-18       Impact factor: 2.175

9.  A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients.

Authors:  Claire J Searle; Ian W Brock; Simon S Cross; Sabapathy P Balasubramanian; Malcolm Wr Reed; Angela Cox
Journal:  Springerplus       Date:  2012-10-23

10.  The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.

Authors:  Annette Künkele; Anja Grosse-Lordemann; Alexander Schramm; Angelika Eggert; Johannes H Schulte; Hagen S Bachmann
Journal:  BMC Cancer       Date:  2013-10-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.